Pulmonology meets rheumatology in sarcoidosis: a review on the therapeutic approach

@article{Drent2014PulmonologyMR,
  title={Pulmonology meets rheumatology in sarcoidosis: a review on the therapeutic approach},
  author={M. Drent and J. Cremers and T. Jansen},
  journal={Current Opinion in Rheumatology},
  year={2014},
  volume={26},
  pages={276–284}
}
Purpose of reviewSarcoidosis is a systemic disease characterized by the formation of granulomas in various organs, mainly lungs and lymphatic system. Joint, muscle, and bone involvement is also rather common. Recent studies on its pathogenesis and therapeutic management are reviewed here. Recent findingsThe pathogenesis of sarcoidosis is not fully elucidated. An exaggerated granulomatous reaction after exposure to unidentified antigens in genetically susceptible individuals evokes a clinical… Expand
Treatment of Sarcoidosis: A Multidisciplinary Approach
  • A. Gerke
  • Medicine
  • Frontiers in Immunology
  • 2020
TLDR
A multidisciplinary treatment approach is summarized, addressing immunuosuppressive drugs, managing complications of chronic granulomatous inflammation, and assessing treatment toxicity. Expand
Anti-TNF therapeutics for the treatment of sarcoidosis.
TLDR
Current knowledge on anti-TNF therapeutics in sarcoidosis is summarized, insights on prediction of response, outcome measures and antibody development are described, and data showing which patients would benefit most from this expensive therapy are scarce are described. Expand
Systemic treatment for sarcoidosis was needed for 16% of 1810 Caucasian patients
TLDR
Evaluating the prevalence of systemic immune‐modulating treatment in a large cohort of sarcoidosis patients to evaluate the frequency of treatment in Caucasian population and data are discordant found to be reliable. Expand
Ulcerative cutaneous sarcoidosis successfully treated with infliximab
TLDR
The clinical features and therapeutic modalities for ulcerative cutaneous sarcoidosis are reviewed and an unusual presentation of a relatively rare cutaneous condition that was treated successfully using infliximab is presented. Expand
Prevalence, distribution and clinical significance of joints, muscles and bones in sarcoidosis: an 18F-FDG-PET/CT study
TLDR
18F-FDG-PET/CT revealed JMBs localizations and coexistence with other organ sites supporting the concept that sarcoidosis is a systemic disease. Expand
Socioeconomic determinants and disparities in sarcoidosis.
TLDR
The known health disparities that exist among patients with sarcoidosis by socioeconomic status, race, and gender are described and interventions to address disparities are proposed including creating educational programs accessible for low-income patients and caregivers, targeting medication adherence and trust in physicians and the medical system, and ensuring access to high-quality care. Expand
Pharmacotherapeutic options in sarcoidosis : how can we improve them?
TLDR
The final author version and the galley proof are versions of the publication after peer review that features the final layout of the paper including the volume, issue and page numbers. Expand
Application of the modified Zajicek criteria to diagnose probable spinal cord neurosarcoidosis
TLDR
Application of the modified Zajicek criteria to diagnose probable spinal neurosarcoidosis in the absence of histology from affected neuronal tissue is highlighted. Expand
Übersicht: Granulomatöse Erkrankungen der Lunge
Das Spektrum pulmonaler Granulomatosen ist breit und beinhaltet infektiöse und nichtinfektiöse Erkrankungen gleichermaßen, die deutlich verschiedene therapeutische Konsequenzen für die Klinik nachExpand
Identifying Novel Biomarkers in Sarcoidosis Using Genome-Based Approaches.
TLDR
Conventional biomarkers used clinically to support a diagnosis and monitor disease progression in patients with sarcoidosis are reviewed. Expand
...
1
2
...

References

SHOWING 1-10 OF 70 REFERENCES
Corticosteroid treatment in sarcoidosis
TLDR
One of the weightiest questions remaining is whether or not these drugs can prevent scarring in patients with a fibrogenic phenotype, and there is clearly a momentum to design multicentric randomised controlled trials with long enough follow-up to answer this pivotal question. Expand
Successful Treatment of Ocular Sarcoidosis with Rituximab
TLDR
A 50-year-old woman who had been facing recurrent severe uveitis involving both the eyes for 3 years, with poor and transitory responses to topical treatments and oral steroid therapy, was referred to the Center for relapsing Uveitis. Expand
[Rheumatologic manifestations of sarcoidosis].
TLDR
Treatment of rheumatologic disorders often involves non steroidal antiinflammatory drugs, corticosteroids and methotrexate, and biological therapies such as the anti-TNFa and theAnti-CD20 were showed to be effective in some case reports of severe and refractory disease. Expand
A concise review of pulmonary sarcoidosis.
TLDR
There is increasing evidence to support that one or more infectious agents may cause sarcoidosis, although this organism may no longer be viable in the patient, and new and more potent antiinflammatory agents have been developed. Expand
Occupational causes of sarcoidosis
TLDR
There is increasing evidence that sarcoidosis can occur in workplace settings in which there is exposure to both foreign antigens and inorganic triggers of inflammation that promote an exuberant granulomatous immune response. Expand
Rituximab as a treatment alternative in sarcoidosis.
TLDR
A 39-year-old woman with a 3-year history of sarcoidosis involving the mediastinum, lungs, and joints received rituximab therapy, which was well tolerated and caused persistent aphonia. Expand
Management of ocular sarcoidosis.
TLDR
Most cases of chronic ocular sarcoidosis respond well to immunosuppressive therapy, however, patients may require combination therapy to achieve and maintain disease control. Expand
Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy
TLDR
It is suggested that MMF is effective in CNS sarcoidosis but not in Sarcoid myopathy, with a corticosteroid sparing effect and a better tolerance profile than other immunosuppressive agents. Expand
Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis
TLDR
Adalimumab appeared successful in sarcoidosis patients with refractory chronic non-infectious uveitis showing improvement in intraocular inflammatory signs as well as in other relevant clinical indicators of disease activity. Expand
Nonsteroidal therapy of sarcoidosis
TLDR
This review summarizes the recent studies of medications used for sarcoidosis with a focus on nonsteroidal therapies and suggests methotrexate and azathioprine may be useful and well tolerated medications as second-line treatment. Expand
...
1
2
3
4
5
...